These results are consistent with limited previous studies [10, 21] demonstrating that wild-type TP53 ovarian cancer cell lines are responsive to Nutlin-3 and extends observations to the second generation MDM2 inhibitor RG7388 currently in early phase clinical trials. Here, TP53 is linked to ovarian cancer.